Category Archives: News

~SOM3355 has the potential to be an alternative to current VMAT2 inhibitors with a significantly improved side effect profile for the treatment of chorea in Huntington´s disease~  SOM Biotech (“SOM” or the “Company”), a clinical-stage drug discovery and development company focused on orphan diseases of the Central Nervous System, today announces that the U.S. Food …

~Data show SOM3355 reduces chorea in patients with Huntingdon’s Disease and has a good safety profile~ ~SOM3355 discovered through SOM Biotech’s proprietary artificial intelligence-based computational technology SOMAI PRO~ SOM Biotech today announces it will be presenting positive Phase 2a data with SOM3355, an oral vesicular monoamine transporter 2 (VMAT2) inhibitor for the symptomatic treatment of …

SOM Biotech performed a presentation at the University of Barcelona Summer Course dedicated to Rare Diseases. The course was held from the 5th to the 9th of July. Dr. Raúl Insa, CEO of the company, performed the presentation on the topic of drug repurposing for Rare Diseases. The main objective of the course was to …

SOM Biotech announces that it has obtained an INNOVATIVE SME seal from the Ministry of Science and Innovation. This distinction recognizes SOM Biotech’s contribution to R&D innovation. The accreditation highlights the innovative business model, based on a pioneering computational chemistry technology that the company has developed to accelerate and streamline the drug discovery and development …

SOM Biotech announces the appointment of Marc Casellas as Chief Financial Officer. Mr Casellas has an extensive finance experience across the healthcare and venture capital sectors, especially in providing financing to life science companies at different stages of growth. Prior to joining SOM Biotech, Marc Casellas most recently served as Chief Financial Officer of Ysios …

SOM Biotech announces its participation in the BIO International Convention 2021 on June 10th – 18th, that will take place digitally. Hosted by the Biotechnology Innovation Organisation, the event is the largest global event for the biotechnology industry that attracts the leading biotech companies, scientists, research institutions, advisors, and qualified investors, providing extensive networking and …

SOM Biotech announces its participation in the BIO-Equity Europe 2021 event on May 17th – 19th, which will take place digitally. Organized by Biocentury and the EBD Group, the BIO-Equity 2021 event attracts leading innovative pharma and biotech companies as well as specialized investors in life sciences. The event enables the exchange of the latest …

SOM Biotech will present results from the Phase 2 clinical study of SOM3355 for the treatment of chorea symptoms in Huntington´s disease at the XXVI World Congress on Parkinson’s Disease and Related Disorders, to be held May 1st – 4th 2021. The International Association for Parkinsonism and Related Disorders (IAPRD) has accepted the abstract for …

SOM Biotech will attend the “AI-Driven Drug Repositioning & Repurposing” digital congress on April 20th – 21st. Organized by Hanson Wade, the “AI-Driven Drug Repositioning & Repurposing” event aims at featuring real-life case studies and experiences from companies that prove that introducing artificial intelligence in drug repurposing and repositioning is a game-changer in the industry, …

SOM Biotech announces its participation in the BIO-Europe Spring 2021 partnering event on March 22nd – 25th, which will take place digitally due to the pandemic situation. Organized by the EBD Group, a global partnering event organizer, the BIO-Europe Spring event attracts leading decision-makers not only from the traditional pharma and biotech sectors but also …